Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
about
The promises of quantitative systems pharmacology modelling for drug developmentWhite paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in childrenResponse-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.Concepts and challenges in quantitative pharmacology and model-based drug development.Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development.Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.Strategies to assess the drug interaction potential in translational medicine.Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationPharmacometrics and the transition to model-based development.Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.Improving productivity with model-based drug development: an enterprise perspective.ASCPT Task Force for advancing pharmacometrics and integration into drug development.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.The current role of model-based drug development.Model-based clinical drug development in the past, present and future: a commentary.Kidney function assessment and its role in drug development, review and utilization.Drug-drug interaction discovery and demystification using Semantic Web technologies.Clinical Trial Design in Juvenile Idiopathic Arthritis.Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)Optimizing drug development in oncology by clinical trial simulation: Why and how?Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.Clinical pharmacology, creating current and future success in drug development.Quantifying pain relief following administration of a novel formulation of paracetamol (acetaminophen).Pharmacometrics 2020.Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor.Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.Use of a biomarker in exposure-response analysis to support dose selection for fingolimod.Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.Mathematical modeling in immunotherapy of cancer: personalizing clinical trials.A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.
P2860
Q28077650-22D38397-E1DA-40C8-9581-5E842C986E02Q30540355-26401C0F-2361-45B8-9833-9981CBEBDD02Q33524423-638E331B-8E87-4135-B193-257F6CB668B0Q33559117-7B8C4DBF-AF56-422A-B77C-616CC45B7AEAQ34226129-20E275AE-2CC1-426C-803D-A19F367B9D4EQ34878168-715D0F7B-8680-4B26-9781-8455F1791230Q35595794-7C967BB5-9FB4-4906-ABAB-75EC0CB65C2EQ36388088-0C58835E-5B1F-4917-8BBC-16A0FA64EC7AQ36536008-133AB36D-440E-4EB1-928C-D7764CF81BD1Q36609743-638D8D76-A40C-4284-A665-E46A0401A3C0Q36734132-8EEA7683-9E70-4126-8306-4D59C7F1DAD2Q36882462-9077FF35-5B88-41D3-9E32-C51D73BFB132Q37149100-2ACEED3C-6EE1-4E7A-9554-6599E5A98BB2Q37521422-73FF28E2-C5FE-4950-BD62-99B68547EACDQ37570459-B1C6EBD7-FFF9-49DB-8136-DC3039862938Q37731854-BE62A90C-61AD-4114-B55E-921D3A41B8C6Q37769100-58F31EA0-4C2F-4B49-85E0-8EA6BEE9AE9EQ37774550-F403D898-A90B-4662-B4A3-472CFDC1F04AQ37886138-DBCBB997-010D-4336-A73C-BF30D304C863Q37927016-8C70744E-E3CF-4AE0-94CE-61F057E226A7Q38028538-96C27F59-5E27-4225-A866-02E46967011CQ38188035-08163624-816D-4592-A8CB-4A6ADA194AEAQ38215907-B91B0D21-81C9-4F2A-9C5D-1EC3F1E7C271Q38383012-19E071BF-90C8-4477-B0C6-6BC7AAFE1168Q38671265-B6CEB299-80EA-46E1-B1A9-146EC9C2908FQ38672541-126C5C36-B5E7-4EA1-BBFA-B029EC784203Q38675644-DC873942-120D-48D3-98BD-40A339A079D8Q38808391-9F58EAC5-8408-434C-A5AF-3D5DEA6C09E7Q39003952-8DFE6353-BAB1-4A0E-BC06-ACFA0A740B09Q39291089-63B84058-24F6-4D44-8F86-A6441120B669Q39828337-4DC1AF8A-E010-480C-9284-76F3B7DBD635Q39828343-9EEE27F3-3657-48A9-9652-063D6ED4A860Q39828349-4B0FC6AB-C0D1-42F1-A850-248E1C8002FFQ41984338-CE6BDD14-4579-474F-9955-411F382664CAQ42578169-FA334D38-FC6A-4BFB-9CEA-EA4BBEA85AB3Q42907115-70EE7C48-B782-4A15-81C5-59D4BDEE3C2BQ42945852-5C704487-0400-465C-BDFF-6F0B94E9FCCBQ43053059-026628BD-44D5-4B75-9D1E-10E061D2492BQ43059458-29BEA158-5224-4780-86BA-9DD2AE4B5255Q44777428-16D3D24B-7B95-4DC2-BFC0-E9C2AB48C875
P2860
Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@ast
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@en
type
label
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@ast
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@en
prefLabel
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@ast
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@en
P2093
P2860
P356
P1433
P1476
Impact of pharmacometrics on d ...... y of 42 new drug applications.
@en
P2093
B Nhi Beasley
Brian P Booth
Chandrahas G Sahajwalla
J Robert Powell
Jogarao V S Gobburu
John Z Duan
Mehul U Mehta
Nam Atiqur Rahman
Patrick J Marroum
Raman K Baweja
P2860
P2888
P304
P356
10.1208/AAPSJ070351
P407
P577
2005-10-07T00:00:00Z
P5875
P6179
1052268149